Where is Zevacor located?

Zevacor is headquartered in Dulles, United States.

How many employees does Zevacor have?

As of Jul 01, 2024, the latest employee count at Zevacor is 25.

Is Zevacor a funded company?

Zevacor is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Zevacor rank among its competitors?

Zevacor ranks 38th amongst 106 active competitors, of which 18 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ionetix, which secured an undisclosed amount in Aug, 2024.

Who are the top competitors of Zevacor?

Zevacor's top competitors include AC Immune, Ionetix and Curium. Among them, Ionetix secured the most recent funding round in August, 2024.

Zevacor - 2026 Company Profile, Team & Competitors

Zevacor is an acquired company based in Dulles (United States), founded in 2013. It operates as a Radiolabeling & radiopharmaceutical manufacturing services for nuclear medicine and molecular imaging. The company has 106 active competitors, including 18 funded and 21 that have exited. Its top competitors include companies like AC Immune, Ionetix and Curium.

Company Details

Zevacor is focussed on developing radiopharmaceutical products and supporting services for use in nuclear medicine and molecular imaging. It provides its services through its subsidiaries Zevacor Pharma and Zevacor Molecular formerly IBA Molecular). Zevacor Molecular manufactures PET and SPECT radiopharmaceuticals and is working on the construction of a new 70 MeV cyclotron and multiple synthesis and processing units for production and distribution of a broad range of clinical and research radioisotopes. Zevacor Pharma provides investigative and custom radiolabeling services to pharmaceutical, biotech, and research institutions nationwide for the development of the next generation of molecular imaging and therapeutic products.

Website: zevacor.com
Social

Key Metrics

Founded Year

2013

Location

Dulles, United States

Stage

Acquired

Ranked

38^th among 106 active competitors

Employee Count

25 as on Jul 01, 2024

Similar Companies

AC Immune & 88 more

Exit Details

Acquired by Curium (Mar 03, 2020)

View Zevacor's full profile

Zevacor got acquired by Curium on Mar 03, 2020.

Click here to take a look at Zevacor's acquisition in detail

Zevacor is a funded company.

Zevacor's employee count trend

Zevacor has 25 employees as of Jul 24. Here is Zevacor's employee count trend over the years:

Uncover Zevacor's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zevacor include AC Immune, Ionetix and Curium. Here is the list of Top 10 competitors of Zevacor, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Redmile Group & 4 others	61/100
2nd	Ionetix 2009, San Francisco (United States), Series C	Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy	$61.1M	Lilly, Riverland Capital & 1 others	56/100
3rd	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest	56/100
4th	RadioMedix 2006, Houston (United States), Series A	Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment	$40M	Military Health, Portland & 1 others	55/100
5th	Niowave 2005, Lansing (United States), Series A	Provider of devices and radioisotopes for nuclear imaging	$9.95M	SBIR, OSTI	53/100
6th	BioTelemetry 1994, Malvern (United States), Acquired	Wireless connected products for health parameters monitoring	-	-	53/100
7th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100
8th	BioArctic 2003, Bromma (Sweden), Public	Developer of disease-modifying treatments for neurodegenerative diseases	-	EQT, EIC Fund & 1 others	51/100
9th	ImaginAb 2007, Los Angeles (United States), Series C	Immune imaging technology for cancer and autoimmune disease management	$59.6M	Adage Capital Management, Novartis & 12 others	51/100
10th	Radiopharmacy 1997, Evansville (United States), Unfunded	Developer of radiopharmaceuticals for imaging purposes	-	-	49/100
38th	Zevacor 2013, Dulles (United States), Acquired	Radiolabeling & radiopharmaceutical manufacturing services for nuclear medicine and molecular imaging	-	-	33/100